Botox® is a brand-name injectable containing onabotulinumtoxinA, used for various pharmacological applications in Canada.

Botox® is a well-known pharmaceutical product manufactured by AbbVie (formerly Allergan). As a brand-name medication, its active ingredient is onabotulinumtoxinA, a protein produced by the bacterium Clostridium botulinum. In the Canadian market, several other competing brands utilize similar botulinum toxin technologies, though they are not biologically identical and cannot be used interchangeably.

This medication stops nerve signals from reaching muscles, which causes the muscles to temporarily relax.

At a biological level, Botox® works by targeting the site where nerves meet muscles. It prevents the release of a chemical messenger called acetylcholine. Without this messenger, the muscle does not receive the signal to contract. This results in a temporary, localized reduction in muscle activity in the specific area where the medication was injected.

It comes as a dried powder in vials, typically in 50, 100, or 200 unit sizes.

In Canada, Botox® is supplied as a sterile, vacuum-dried purified neurotoxin complex. It does not come as a pre-mixed liquid; instead, it must be reconstituted (mixed) with a sterile saline solution by a healthcare professional before it can be administered.

A healthcare professional must prepare and inject this medication directly into the target muscle or tissue.

• Administration: This medication is only for injection by a qualified doctor or trained specialist.
• Customization: The exact number of units and the specific injection sites are determined by the practitioner based on pharmaceutical guidelines.
• Frequency: The effects are temporary, usually lasting several months, and repeat sessions must be spaced out according to the product monograph to ensure safety.